ReviewMolecular biology reports2026
Glycolysis in bone remodeling: from energy supply to signaling regulation.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Maintenance of bone homeostasis depends on the precise balance between bone formation and bone resorption, a process profoundly regulated by energy metabolism. The glycolytic pathway has emerged as a key determinant of osteoblast and osteoclast fate, functioning beyond energy supply. This review summarizes how multiple signals (e.g., hypoxia-inducible factor-1α/Wnt) promote glycolysis during bone remodeling and highlights that glycolytic enzymes and metabolites (e.g., lactate, lactate dehydrogenase, pyruvate dehydrogenase kinase) act as a "signaling hub" that regulates cell differentiation and function. Cumulative evidence indicates that interfering with specific glycolytic pathways can regulate bone cell differentiation through both energy supply and nonmetabolic signaling mechanisms, providing a novel perspective for understanding bone metabolic diseases. We propose that the glycolytic pathway may function as a signaling hub that integrates metabolic status and regulation of the fate of bone cells. Targeting key nodes of this network represents a promising but preliminary therapeutic direction, and further in vivo and clinical studies are warranted to verify its translational value.
Indexed as
Identifiers
42801354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.